Global Human Serum Albumin Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Human Serum Albumin Market Research Report 2024
Albumin is a water-soluble globular protein produced in the liver. It accounts for 50% of blood plasma proteins. These play a vital role in regulating blood volume and act as transporters for molecules such as few hormones, bile salts, and ions. Albumin is commonly used as blood volumizer in rare diseases, burns, shocks, liver conditions, and other blood loss trauma and surgeries.
According to Mr Accuracy reports’s new survey, global Human Serum Albumin market is projected to reach US$ 8367.2 million in 2034, increasing from US$ 5109.6 million in 2022, with the CAGR of 7.3% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Human Serum Albumin market research.
The key global producers of human serum albumin are Grifols, CSL, Takeda, Octapharma, CBPO, Hualan Bio, Kedrio, and Shanghai RAAS, with the top four manufacturers together holding 60% of the market share. The largest producer is CSL with a market share of 21.25%. In terms of consumption level, the market is mainly distributed in North America, Europe and Asia Pacific, with Asia Pacific having the highest market share of 68.63%. In terms of its product type, human serum albumin with 20-25% concentration holds the major market share with 90%, while 5% concentration accounts for a smaller share. In terms of its application, therapeutic is its top application area, accounting for 80% of the market share.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Human Serum Albumin market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Grifols
CSL
Takeda
Octapharma
CBPO
Hualan Bio
Kedrion
Shanghai RAAS
LFB Group
Biotest
Tiantan Bio
Shuanglin Bio
Boya Bio
Yuanda Shuyang
Weiguang Bio
Segment by Type
20-25% Concentrations
5% Concentrations
Therapeutics
Excipient
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Human Serum Albumin report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Human Serum Albumin market is projected to reach US$ 8367.2 million in 2034, increasing from US$ 5109.6 million in 2022, with the CAGR of 7.3% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Human Serum Albumin market research.
The key global producers of human serum albumin are Grifols, CSL, Takeda, Octapharma, CBPO, Hualan Bio, Kedrio, and Shanghai RAAS, with the top four manufacturers together holding 60% of the market share. The largest producer is CSL with a market share of 21.25%. In terms of consumption level, the market is mainly distributed in North America, Europe and Asia Pacific, with Asia Pacific having the highest market share of 68.63%. In terms of its product type, human serum albumin with 20-25% concentration holds the major market share with 90%, while 5% concentration accounts for a smaller share. In terms of its application, therapeutic is its top application area, accounting for 80% of the market share.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Human Serum Albumin market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Grifols
CSL
Takeda
Octapharma
CBPO
Hualan Bio
Kedrion
Shanghai RAAS
LFB Group
Biotest
Tiantan Bio
Shuanglin Bio
Boya Bio
Yuanda Shuyang
Weiguang Bio
Segment by Type
20-25% Concentrations
5% Concentrations
Segment by Application
Therapeutics
Excipient
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Human Serum Albumin report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices